Email contact via H. Lundbeck A/S

Trials

Studies that name Email contact via H. Lundbeck A/S as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 11:58 UTC. Open this list on ClinicalTrials.gov

• Ph2
  NCT07859293 · An Extension Trial of Asedebart in Participants With Congenital Adrenal Hyperplasia

  H. Lundbeck A/S · not yet recruiting · Adrenal Hyperplasia, Congenital · study director
• Ph1
  NCT07775261 · A Trial of Lu AH69593 in Healthy Participants

  H. Lundbeck A/S · recruiting · Healthy Participants · study director
• Ph1
  NCT07613710 · A Trial to Test the Safety and Tolerability of Lu AH69593 in Adults That Are Healthy or Have Narcolepsy

  H. Lundbeck A/S · recruiting · Narcolepsy · study director
• Ph1
  NCT07513441 · A Trial of Lu AF28996 in Participants With Parkinson's Disease (PD)

  H. Lundbeck A/S · recruiting · Parkinson Disease · study director
• Ph2
  NCT07514858 · A Trial Investigating Lu AF28996 in Adults With Parkinson's Disease Who Have Motor Fluctuations

  H. Lundbeck A/S · recruiting · Parkinson's Disease · study director
• Ph3
  NCT06706622 · A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA)

  H. Lundbeck A/S · active not recruiting · Multiple System Atrophy · study director
• Ph4
  NCT06701526 · A Trial of Eptinezumab in Participants With Migraine and Insufficient Response to Anti-CGRP Medications

  H. Lundbeck A/S · completed · Migraine · study director
• Ph1
  NCT06578585 · A Trial Investigating Lu AG09222 With Ubrogepant in Participants With Migraine

  H. Lundbeck A/S · completed · Migraine · study director
• Ph2
  NCT06471829 · A Trial of Lu AG13909 in Adult Participants With Cushing's Disease

  H. Lundbeck A/S · active not recruiting · Cushing's Disease · study director
• Ph2
  NCT06323928 · A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  H. Lundbeck A/S · completed · Migraine · study director
• Ph1
  NCT06258720 · A Trial Investigating Lu AF82422 in Healthy Chinese and Caucasian Adults

  H. Lundbeck A/S · completed · Healthy Participants · study director
• Ph1
  NCT06077786 · A Trial Investigating the Pain-relieving Properties of Lu AG06474 in Healthy Adult Participants

  H. Lundbeck A/S · completed · Healthy Participants · study director
• Ph1
  NCT06004180 · A Trial Investigating Lu AF28996 in Adult Japanese Participants With Parkinson's Disease (PD)

  H. Lundbeck A/S · completed · Parkinson Disease · study director
• Ph3
  NCT05897320 · A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

  H. Lundbeck A/S · recruiting · Episodic Migraine · study director
• Ph1/Ph2
  NCT05669950 · A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia

  H. Lundbeck A/S · recruiting · Congenital Adrenal Hyperplasia · study director
• N/A
  NCT05453058 · Observational Study in Multiple System Atrophy

  H. Lundbeck A/S · active not recruiting · Multiple System Atrophy · study director
• Ph4
  NCT05452239 · A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  H. Lundbeck A/S · completed · Migraine, Medication Overuse Headache · study director
• Ph1
  NCT05320302 · A Brain Imaging PET Study of [11C]-Lu AF88370 in Healthy Adult Male Participants

  H. Lundbeck A/S · completed · Healthy Participants · study director
• Ph1
  NCT05306366 · A Brain Imaging PET Study of [11C]-Lu AF90103 in Healthy Adult Male Participants

  H. Lundbeck A/S · completed · Healthy Young Men · study director
• Ph1
  NCT05304910 · A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants

  H. Lundbeck A/S · completed · Migraine · study director
• Ph4
  NCT05284019 · Real World Effectiveness of Eptinezumab in Participants With Migraine

  H. Lundbeck A/S · terminated · Migraine · study director
• Ph1
  NCT05177029 · Safety and Tolerability Study of Lu AG06466 in Healthy Young Japanese and Caucasian Participants

  H. Lundbeck A/S · terminated · Healthy Volunteers · study director
• Ph3
  NCT05164172 · A Study With Eptinezumab in Children and Adolescents (6 to 17 Years) With Chronic or Episodic Migraine

  H. Lundbeck A/S · recruiting · Migraine · study director
• Ph1
  NCT05136053 · A Study Investigating Lu AG22515 in Healthy Adults

  H. Lundbeck A/S · completed · Healthy Participants · study director
• Ph2
  NCT05133323 · A Study With Lu AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments

  H. Lundbeck A/S · completed · Migraine · study director
• Ph1
  NCT05126316 · A Trial to Learn More About Repeated Monthly Injections of Lu AG09222 in Participants With Allergies to Grass Pollen

  H. Lundbeck A/S · completed · Allergic Rhinitis · study director
• Ph2
  NCT05104476 · A Study of Lu AF82422 in Participants With Multiple System Atrophy

  H. Lundbeck A/S · active not recruiting · Multiple System Atrophy · study director
• Ph1
  NCT05081518 · A Study of Lu AG06466 in Participants With Treatment Resistant Focal Epilepsy

  H. Lundbeck A/S · terminated · Focal Epilepsy · study director
• Ph1
  NCT05074459 · A Study in Healthy Adults Investigating Eptinezumab Produced by 2 Different Manufacturing Cell Lines

  H. Lundbeck A/S · completed · Healthy Participants · study director
• Ph3
  NCT05064397 · A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)

  H. Lundbeck A/S · completed · Chronic Cluster Headache · study director
• Ph3
  NCT05064371 · Long-Term Extension Study With Eptinezumab as Preventive Treatment in Participants With Migraine in Japan

  H. Lundbeck A/S · completed · Migraine · study director
• Ph1
  NCT05045781 · Safety, Tolerability and Pharmacokinetics of Eptinezumab in Healthy Chinese Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT05003687 · Safety and Tolerability of Lu AG06474 in Healthy Young Men

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT04990219 · A Study of Lu AG06466 for the Treatment of Spasticity in Participants With Multiple Sclerosis

  H. Lundbeck A/S · terminated · Multiple Sclerosis · study director
• Ph1
  NCT04976309 · A Single Dose Study of Lu AG09222 in a Headache Model With Healthy Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT04974359 · A Study to Evaluate Lu AG06466 in Participants With Fibromyalgia

  H. Lundbeck A/S · terminated · Fibromyalgia · study director
• Ph3
  NCT04965675 · A Study With Eptinezumab in Adolescents (12-17 Years) With Chronic Migraine

  H. Lundbeck A/S · recruiting · Chronic Migraine in Children · study director
• Ph1
  NCT04940949 · A Study to Evaluate Lu AF90103 in Healthy Men

  H. Lundbeck A/S · terminated · Healthy · study director
• Ph3
  NCT04921384 · Eptinezumab as Preventive Treatment of Migraine in Adults With Migraine

  H. Lundbeck A/S · completed · Migraine · study director
• Ph3
  NCT04772742 · Eptinezumab in Adults With Migraine and Medication Overuse Headache

  H. Lundbeck A/S · completed · Migraine, Medication Overuse Headache · study director
• Ph1
  NCT04713254 · Drug Drug Interaction Study With Lu AG06466 in Young Healthy Men

  H. Lundbeck A/S · completed · Healthy · study director
• Ph3
  NCT04688775 · Eptinezumab in Participants With Episodic Cluster Headache

  H. Lundbeck A/S · completed · Cluster Headache, Episodic · study director
• Ph1
  NCT04597450 · Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

  H. Lundbeck A/S · completed · PTSD · study director
• Ph1
  NCT04538014 · A Study in Healthy Men to Investigate Uptake and Distribution of Lu AF88434 in the Brain

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT04537429 · A Study in Children and Young People With Migraine to Learn What the Body Does to Eptinezumab

  H. Lundbeck A/S · completed · Migraine in Children, Migraine · study director
• Ph1
  NCT04473651 · Safety and Tolerability of Lu AG06479 in Healthy Young Men

  H. Lundbeck A/S · terminated · Healthy · study director
• Ph4
  NCT04448431 · Comparison of Vortioxetine and Desvenlafaxine in Adult Patients Suffering From Depression

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph1
  NCT04419636 · Binding of Lu AG06466 in the Brain in Healthy Men

  H. Lundbeck A/S · completed · Healthy · study director
• Ph3
  NCT04418765 · A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

  H. Lundbeck A/S · completed · Migraine · study director
• Ph1
  NCT04405323 · Study That Evaluates the Effect of CYP3A4 Inhibition on Lu AG06466 in Healthy Men and Women

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT04336449 · Eptinezumab in Healthy Japanese Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT04322227 · Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

  H. Lundbeck A/S · terminated · Parkinson Disease, Healthy · study director
• Ph4
  NCT04294654 · Vortioxetine in Patients With Depression and Early Dementia

  H. Lundbeck A/S · completed · Major Depressive Disorder, Dementia · study director
• Ph1
  NCT04291859 · Lu AF28996 in Participants With Parkinson's Disease (PD)

  H. Lundbeck A/S · completed · Parkinson Disease · study director
• Ph4
  NCT04288895 · Open-label, Flexible-dose Study of Vortioxetine in Patients With Depression in India

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph1
  NCT04275115 · Effects of Repeated Doses of Foliglurax on Drug Metabolizing Enzymes in Healthy Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph4
  NCT04220996 · Vortioxetine in Patients With Depression Coexisting With General Anxiety Disorder (GAD)

  H. Lundbeck A/S · completed · MDD, Anxiety Disorders · study director
• Ph1
  NCT04199585 · Safety and Tolerability of Lu AF95245 in Healthy Young Men

  H. Lundbeck A/S · terminated · Healthy · study director
• Ph1
  NCT04197349 · Safety, Tolerability and Pharmacokinetics of ALD1910 in Healthy Men and Woman

  H. Lundbeck A/S · completed · Migraine · study director
• Ph1
  NCT04175132 · Binding of Foliglurax to Regions in the Brain in Healthy Participants and in Patients With Parkinson's Disease (PD)

  H. Lundbeck A/S · terminated · Healthy, Parkinson Disease · study director
• Ph3
  NCT04152083 · A Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Participants Experiencing Acute Attack of Migraine

  H. Lundbeck A/S · completed · Migraine · study director
• Ph1
  NCT04149860 · Study With Lu AF87908 in Healthy Participants and Participants With Alzheimer's Disease

  H. Lundbeck A/S · completed · Healthy, Alzheimer Disease · study director
• Ph1
  NCT04104503 · A Study Investigating Tablet Formulations of Lu AF11167 in Healthy Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT04082325 · Study Investigating the Safety and Tolerability of Lu AF88434 in Healthy Young Men

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT04002895 · What the Body Does to Foliglurax in Healthy Volunteers

  H. Lundbeck A/S · completed · Healthy · study director
• Ph2
  NCT03929497 · Flexible-dose Long-term Extension Study of Lu AF11167 in Patients With Schizophrenia With Prominent Negative Symptoms

  H. Lundbeck A/S · terminated · Schizophrenia · study director
• Ph1
  NCT03884491 · A Study Investigating Formulations of Vortioxetine Applied Under the Tongue in Healthy Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph4
  NCT03835715 · Study With Vortioxetine on Emotional Functioning in Patients With Depression

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph1
  NCT03819699 · Study With Lu AF20513 in Patients With Mild Alzheimer's Disease (AD) or Mild Cognitive Impairment (MCI) Due to AD

  H. Lundbeck A/S · terminated · Alzheimer Disease · study director
• Ph2
  NCT03793712 · Study With Lu AF11167 for the Treatment of Negative Symptoms in Patients With Schizophrenia

  H. Lundbeck A/S · terminated · Schizophrenia · study director
• Ph2
  NCT03766867 · Vortioxetine Intravenous Infusion at Initiation of Oral Treatment With Vortioxetine in Patients With Depression

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph1
  NCT03670095 · Study in Healthy Subjects to Compare Two Tablet Formulations of Memantine (Ebixa®) in Fasted and Fed Conditions

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT03670082 · Study With Lu AF35700 in Healthy Men and Women in Fasting and Fed State

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT03668405 · A Study to Evaluate the Long-term Safety and Tolerability of Lu AF20513 and the Antibody Response in Patients With Alzheimer's Disease (AD)

  H. Lundbeck A/S · terminated · Alzheimer's Disease · study director
• Ph1
  NCT03611569 · Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease

  H. Lundbeck A/S · completed · Healthy, Parkinson Disease · study director
• Ph1
  NCT03565094 · Single Dose of Lu AF28996 to Healthy Young Men

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT03531229 · Single Ascending Dose Study of Lu AF76432 in Healthy Young Men

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT03472651 · Bioequivalence Study to Compare Two Formulations of Deanxit®

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT03307993 · Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease

  H. Lundbeck A/S · terminated · Alzheimer's Disease · study director
• Ph1
  NCT03241147 · Pharmacokinetics of Lu AF35700 in Subjects With Renal Impairment

  H. Lundbeck A/S · terminated · Renal Failure · study director
• Ph1
  NCT03195946 · Effects of Repeated Doses of Lu AF35700 on Drug Metabolizing Enzymes

  H. Lundbeck A/S · completed · Drug Reactions · study director
• Ph1
  NCT03189615 · Study Investigating the Pharmacokinetic Properties of the Drug Lu AF35700 in Subjects With Liver Impairment and in Healthy Subjects

  H. Lundbeck A/S · completed · Hepatic Impairment · study director
• Ph3
  NCT03108625 · Continuation With Vortioxetine in Child and Adolescent Patients With Major Depressive Disorder (MDD) From 7 to 17 Years of Age

  H. Lundbeck A/S · completed · Depressive Disorder, Major · study director
• Ph1
  NCT03103646 · Study Evaluating the Effect of Multiple Doses of Itraconazole on the Drug Lu AF35700 in Healthy Young Men and Women

  H. Lundbeck A/S · completed · Cytochrome P450 Interaction · study director
• Ph2
  NCT02919501 · Study of the Efficacy and Safety of Initial Administration of 17 mg Vortioxetine Intravenously With 10 mg/Day Vortioxetine Orally in Patients With Major Depressive Disorder

  H. Lundbeck A/S · completed · Depressive Disorder, Major · study director
• Ph1
  NCT02901587 · Study Investigating the Effect of Lu AF35700 on Cardiac Repolarization in Men and Women With Schizophrenia and Schizoaffective Disorder

  H. Lundbeck A/S · completed · Schizophrenia, Schizoaffective Disorder · study director
• Ph1
  NCT02894515 · Bioequivalence Study of Idalopirdine in Healthy Subjects

  H. Lundbeck A/S · withdrawn · Bioequivalence · study director
• Ph3
  NCT02892422 · Flexible-dose, Long-term Safety Study of Lu AF35700 in Adult Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT02871297 · Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age

  H. Lundbeck A/S · terminated · Depressive Disorder, Major · study director
• Ph3
  NCT02758067 · Comparison of the Effectiveness of Brexpiprazole With That of Risperidone

  H. Lundbeck A/S · withdrawn · Schizophrenia · study director
• Ph3
  NCT02717195 · Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT02709746 · Active Reference (Fluoxetine) Fixed-dose Study of Vortioxetine in Paediatric Patients Aged 12 to 17 Years With Major Depressive Disorder (MDD)

  H. Lundbeck A/S · completed · Depressive Disorder, Major · study director
• Ph1
  NCT02660840 · Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations

  H. Lundbeck A/S · completed · Bioequivalence Study in Healthy Subjects · study director
• Ph1
  NCT02649608 · An Exploratory Study Investigating Safety, Tolerability and Pharmacokinetics of Ascending Doses of Lu AE04621 in Parkinson Disease Patients

  H. Lundbeck A/S · completed · Parkinson Disease · study director
• Ph4
  NCT02586623 · Sustained Effect of Droxidopa in Symptomatic Neurogenic Orthostatic Hypotension

  H. Lundbeck A/S · completed · Symptomatic Neurogenic Orthostatic Hypotension · study director
• Ph4
  NCT02553928 · Comparison of Once Daily and Twice Daily Dosing on Safety and Tolerability of Memantine in Patients With Alzheimer

  H. Lundbeck A/S · completed · Alzheimer Dementia (AD) · study director
• Ph1
  NCT02436486 · Study Investigating the Effect of Idalopirdine on Cardiac Repolarisation in Healthy Men

  H. Lundbeck A/S · completed · Healthy Volunteers · study director
• Ph3
  NCT02400346 · Evaluation of the Safety of Adjunct Brexpiprazole in Elderly Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Treatment

  H. Lundbeck A/S · completed · Major Depression Disorder · study director
• Ph1
  NCT02388152 · Study to Evaluate the Safety and Tolerability of a New Drug Named Lu AF20513 in Patients With Mild Alzheimer's Disease

  H. Lundbeck A/S · terminated · Alzheimer Disease · study director
• Ph1
  NCT02386488 · Pharmacokinetic Properties of Vortioxetine in Healthy Young Chinese Men and Women

  H. Lundbeck A/S · completed · Pharmacokinetics · study director
• Ph1
  NCT02371707 · Bioequivalence Study of Idalopirdine Tablets 60 mg

  H. Lundbeck A/S · completed · Healthy · study director
• Ph2
  NCT02327013 · Investigating the Effect of Vortioxetine in Adult ADHD Patients

  H. Lundbeck A/S · completed · Attention Deficit Hyperactivity Disorder · study director
• Ph3
  NCT02279953 · Efficacy of Vortioxetine on Cognitive Dysfunction in Patients With Partial or Full Remission of Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT02279966 · Efficacy of Vortioxetine on Cognitive Dysfunction in Working Patients With Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph1
  NCT02231450 · Pharmacokinetics Properties of Single Oral Dosing of Lu AE58054 in Subjects With Hepatic Impairment (Mild and Moderate) and in Healthy Subjects

  H. Lundbeck A/S · completed · Heptic Impairment · study director
• Ph1
  NCT02199431 · Study to Evaluate the Effect of a Known and Marketed Product, Itraconazole (Mycosis Treatment) on Lu AF11167 Entering the Body and Subsequently Elimination. The Study is a Drug-drug Interaction Study in Healthy Volunteers.

  H. Lundbeck A/S · completed · Healthy · study director
• Ph4
  NCT02195817 · Study of 18 mg Selincro® As-needed Use, in the Treatment of Patients With Alcohol Dependence in Primary Care

  H. Lundbeck A/S · terminated · Alcohol Dependence · study director
• Ph3
  NCT02187809 · Safety and Tolerability of Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

  H. Lundbeck A/S · terminated · Dravet Syndrome · study director
• Ph1
  NCT02179931 · Bioequivalence Study in Healthy Men and Women to Compare Two Pharmaceutical Formulations of Flupentixol/Melitracen (Deanxit®)

  H. Lundbeck A/S · completed · Healthy Men and Women · study director
• Ph3
  NCT02174094 · Clobazam as Adjunctive Therapy in Paediatric Patients Aged ≥1 to ≤16 Years With Dravet Syndrome

  H. Lundbeck A/S · withdrawn · Dravet Syndrome · study director
• N/A
  NCT02131415 · Real Life Assessment of Abilify Maintena

  Lundbeck Canada Inc. · terminated · Schizophrenia · study director
• Ph1
  NCT02122692 · Effect of Multiple Doses of Itraconazole on the Multiple Dose Pharmacokinetics of Lu AE58054 in Healthy Subjects

  H. Lundbeck A/S · completed · Healthy Volunteers · study director
• Ph1
  NCT02112903 · Study Comparing the Gastro-intestinal Tolerability and Absorption Profile of Vortioxetine After Administration of Modified-release Formulations and Immediate-release Formulation in Healthy Women

  H. Lundbeck A/S · completed · Healthy Women · study director
• Ph1
  NCT02093169 · D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound

  H. Lundbeck A/S · completed · Healthy Men · study director
• Ph3
  NCT02079246 · Long-term Safety and Tolerability of Idalopirdine (Lu AE58054) as Adjunctive Treatment to Donepezil in Patients With Mild-moderate Alzheimer's Disease

  H. Lundbeck A/S · completed · Alzheimer's Disease · study director
• Ph1
  NCT02072278 · Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects

  H. Lundbeck A/S · completed · Healthy Men · study director
• Ph1
  NCT02019394 · Absolute Bioavailability of Lu AE58054 in Healthy Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph3
  NCT02006641 · Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

  H. Lundbeck A/S · completed · Alzheimer's Disease · study director
• Ph3
  NCT02006654 · Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With an Acetylcholinesterase Inhibitor

  H. Lundbeck A/S · completed · Alzheimer's Disease · study director
• Ph3
  NCT01987960 · Brexpiprazole as an Adjunctive Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)

  H. Lundbeck A/S · terminated · Post-traumatic Stress Disorder, PTSD · study director
• Ph1
  NCT01975779 · Study Investigating the Safety, Tolerability, and Pharmacokinetic Properties of Lu AE58054 in Healthy Japanese and Caucasian Subjects

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT01969617 · Effects of Nalmefene After Single Dose on the Blood Oxygen Level Dependent (BOLD) fMRI Signal in the Ventral Striatum to Reward Responding in the Monetary Incentive Delay Task (MIDT), in Non-treatment Seeking Subjects With Alcohol Dependence Following Alcohol Challenge

  H. Lundbeck A/S · completed · Alcohol Dependence · study director
• Ph3
  NCT01959035 · Aripiprazole Once-monthly in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT01955161 · Study of Idalopirdine in Patients With Mild - Moderate Alzheimer's Disease Treated With Donepezil

  H. Lundbeck A/S · completed · Alzheimer's Disease · study director
• Ph3
  NCT01944969 · Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

  H. Lundbeck A/S · terminated · Major Depressive Disorder · study director
• Ph3
  NCT01942785 · Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

  H. Lundbeck A/S · completed · Major Depressive Disorder, Irritability · study director
• Ph3
  NCT01942733 · Study of Brexpiprazole as Adjunctive Treatment of Sleep Disturbances in Patients With Major Depressive Disorder

  H. Lundbeck A/S · completed · Sleep Disturbances · study director
• Ph1
  NCT01934166 · Pharmacokinetic Properties of Nalmefene in Subjects With Renal Impairment and in Healthy Subjects

  H. Lundbeck A/S · completed · Renal Impairment · study director
• Ph3
  NCT01838681 · Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT01837797 · Efficacy and Safety of Brexpiprazole as Adjunctive Treatment in Elderly Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

  H. Lundbeck A/S · terminated · Major Depressive Disorder · study director
• Ph3
  NCT01810783 · Brexpiprazole in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT01810380 · Brexpiprazole in Patients With Acute Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT01795547 · Aripiprazole Once-monthly Versus Paliperidone Palmitate in Adult Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph1
  NCT01676571 · Pharmacokinetic Properties of Lu AA21004 (Vortioxetine) in Healthy Young Chinese Men and Women

  H. Lundbeck A/S · completed · Healthy · study director
• Ph1
  NCT01652313 · Pharmacokinetic Properties of Rasagiline (Lu 00-773) in Healthy Young Chinese Men and Women

  H. Lundbeck A/S · completed · Parkinson's Disease · study director
• Ph1
  NCT01607125 · Exploratory Study of the Effects of Vortioxetine (Lu AA21004) on Cognition and Blood Oxygen Level Dependent (BOLD) Functional Magnetic Resonance Imaging (fMRI) Signals in Subjects Remitted From Depression and in Controls

  H. Lundbeck A/S · completed · Depression · study director
• Ph3
  NCT01571453 · Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT01556165 · Rasagiline in Early Parkinson's Disease Patients Not Treated With Levodopa in China

  H. Lundbeck A/S · completed · Parkinson's Disease · principal investigator
• Ph3
  NCT01500083 · Bendamustine Hydrochloride (HCl) in Indolent Non-Hodgkin's Lymphoma That Has Progressed During or Following Treatment With a Rituximab Regimen or Previously Untreated Chronic Lymphocytic Leukemia

  Lundbeck Canada Inc. · completed · Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia · study director
• Ph2
  NCT01491035 · Pharmacokinetics and Tolerability of Vortioxetine (Lu AA21004) in Child and Adolescent Patients With Depressive or Anxiety Disorder

  H. Lundbeck A/S · completed · Depressive Disorder, Anxiety Disorder · study director
• Ph3
  NCT01488071 · A Study of Vortioxetine (Lu AA21004) in Comparison to Agomelatine in Adults Suffering From Major Depression With Inadequate Response to Previous Medication

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT01479530 · Azilect® (Rasagiline) in Levodopa-treated Parkinson's Patients With Motor Fluctuations in China

  H. Lundbeck A/S · completed · Parkinson's Disease · study director
• N/A
  NCT01427439 · A Prospective Epidemiological Research on Functioning Outcomes Related to Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT01422213 · Efficacy Study of Vortioxetine on Cognitive Dysfunction in Adult Patients With Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph4
  NCT01413711 · An Open-Label, Single and Multiple Oral Dose Pharmacokinetic Study of Vigabatrin in Infants With Infantile Spasms

  Lundbeck LLC · withdrawn · Infantile Spasms · study director
• Ph1
  NCT01395433 · Bioequivalence Study Comparing Two Formulations of Escitalopram

  H. Lundbeck A/S · completed · Healthy · study director
• Ph2
  NCT01377233 · Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT01323478 · Open-label Safety Extension Study of 15 and 20 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT01295372 · Safety and Efficacy of Zicronapine in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph4
  NCT01278173 · A Study of the Structure and Function of the Retina in Adult Patients With Refractory Complex Partial Seizures Treated With Vigabatrin (Sabril®)

  Lundbeck LLC · completed · Adult Refractory Complex Partial Seizures · study director
• Ph3
  NCT01268891 · Study of Azilect® (Rasagiline) in Levodopa-treated Parkinson's Disease Patients With Motor Fluctuations in Korea

  H. Lundbeck A/S · completed · Parkinson's Disease · study director
• Ph3
  NCT01160770 · Safety and Effectiveness of Open-Label Clobazam in Subjects With Lennox-Gastaut Syndrome

  Lundbeck LLC · completed · Lennox-Gastaut Syndrome · study director
• Ph4
  NCT01148472 · Efficacy and Tolerability of Escitalopram and Duloxetine in Outpatients With Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT01140906 · Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 15 and 20 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT01128959 · Study to Assess the Safety and Tolerability of Intravenous Carbamazepine in Adults With Epilepsy

  Lundbeck LLC · completed · Epilepsy · study director
• Ph2
  NCT01104467 · Clinical Study of Desmoteplase in Japanese Patients With Acute Ischemic Stroke

  Lundbeck Japan K. K. · completed · Acute Ischemic Stroke · study director
• Ph1
  NCT01079351 · A Study of the Pharmacokinetics (PK) and Safety of IV Carbamazepine Relative to Oral Carbamazepine in Adults With Epilepsy

  Lundbeck LLC · completed · Epilepsy · study director
• N/A
  NCT01073579 · Sabril Patient Registry

  Lundbeck LLC · completed · Infantile Spasms, Refractory Complex Partial Seizures in Adults · study director
• Ph4
  NCT01055379 · Rasagiline in Cognitive-impairment Related Depression: AzileCt in COgnitive-impairment Related DepressiOn

  Lundbeck Italia S.p.A. · completed · Depressive Symptoms, Parkinson's Disease · study director
• Ph2
  NCT01019421 · Lu AE58054 Added to Donepezil for the Treatment for Moderate Alzheimer's Disease

  H. Lundbeck A/S · completed · Alzheimer's Disease · study director
• Ph2
  NCT01016366 · Safety Study of Carbamylated Erythropoietin to Treat Patients With the Neurodegenerative Disorder Friedreich's Ataxia

  H. Lundbeck A/S · completed · Friedreich's Ataxia · study director
• Ph4
  NCT00902564 · Escitalopram in Patients With Generalized Anxiety Disorder

  H. Lundbeck A/S · completed · Generalized Anxiety Disorder · study director
• Ph1
  NCT00870844 · Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

  H. Lundbeck A/S · completed · Acute Ischemic Stroke · study director
• Ph3
  NCT00864045 · Sertindole in Asian Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph4
  NCT00862940 · A Clinical Study Evaluating the Effects of Memantine on Brain Atrophy in Patients With Alzheimer's Disease

  H. Lundbeck A/S · completed · Alzheimer's Disease · study director
• Ph3
  NCT00861497 · Bifeprunox Extension to Extension Study in Patients With Schizophrenia

  H. Lundbeck A/S · terminated · Schizophrenia · study director
• Ph3
  NCT00857233 · Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease

  H. Lundbeck A/S · terminated · Alzheimer's Disease · study director
• Ph3
  NCT00857649 · Efficacy and Safety of Memantine in Moderate to Severe Alzheimer's Disease

  H. Lundbeck A/S · terminated · Alzheimer's Disease · study director
• Ph3
  NCT00856583 · Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT00856661 · Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke (DIAS-4)

  H. Lundbeck A/S · terminated · Stroke · study director
• Ph4
  NCT00855686 · Memantine Versus Placebo in Parkinson's Disease Dementia or Dementia With Lewy Bodies

  H. Lundbeck A/S · completed · Parkinson's Disease Dementia, Dementia With Lewy Bodies · study director
• Ph2
  NCT00839423 · Randomised Placebo-controlled Venlafaxine-referenced Study of Efficacy and Safety of 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Adults

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT00812461 · Efficacy of Nalmefene in Patients With Alcohol Dependence

  H. Lundbeck A/S · completed · Alcohol Dependence · study director
• Ph3
  NCT00811720 · Efficacy of Nalmefene in Patients With Alcohol Dependence

  H. Lundbeck A/S · completed · Alcohol Dependence · study director
• Ph3
  NCT00811941 · Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence

  H. Lundbeck A/S · completed · Alcohol Dependence · study director
• Ph3
  NCT00811252 · Randomised Placebo-controlled Duloxetine-referenced Study of Efficacy and Safety of 5 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder in Elderly Patients

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph2
  NCT00810667 · Efficacy Study Exploring the Effect of Lu AE58054 as Augmentation Therapy in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia, Cognition · study director
• Ph2
  NCT00807248 · Short-term Study of Combination Treatment of Escitalopram and Gaboxadol in Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT00790920 · Efficacy and Safety Study of Desmoteplase to Treat Acute Ischemic Stroke

  H. Lundbeck A/S · completed · Stroke · study director
• Ph3
  NCT00788034 · Relapse-prevention Study With Lu AA21004 (Vortioxetine) in Patients With Generalized Anxiety Disorder

  H. Lundbeck A/S · completed · Generalized Anxiety Disorder · study director
• Ph2
  NCT00771134 · Efficacy and Safety of Lu AA39959 in Patients With Bipolar Depression

  H. Lundbeck A/S · terminated · Bipolar Disorder · study director
• Ph2
  NCT00770744 · Efficacy of Lu 31-130 in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph2
  NCT00768326 · Efficacy of Lu 31-130 in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph2
  NCT00766870 · Efficacy and Safety of Lu AA34893 in Patients With Major Depressive Disorder

  H. Lundbeck A/S · terminated · Major Depressive Disorder · study director
• Ph4
  NCT00763438 · Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph2
  NCT00761306 · Open-label Safety Extension Study of 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT00759460 · Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph3
  NCT00759421 · Exploratory Cognition Study of Sertindole in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia · study director
• Ph1
  NCT00756249 · Safety Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

  H. Lundbeck A/S · completed · Acute Ischemic Stroke · study director
• Ph3
  NCT00704509 · Efficacy of Bifeprunox in Patients With Schizophrenia

  H. Lundbeck A/S · terminated · Schizophrenia · study director
• Ph3
  NCT00694304 · Open-label Safety Extension Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Long-term Treatment of Major Depressive Disorder in Adults

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT00658645 · Efficacy of Bifeprunox in Patients With Schizophrenia

  H. Lundbeck A/S · terminated · Schizophrenia · study director
• Ph3
  NCT00654706 · Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia

  H. Lundbeck A/S · completed · Schizophrenia, Cognition · study director
• Ph3
  NCT00635219 · Randomised Placebo-controlled Duloxetine-referenced Efficacy and Safety Study of 2.5, 5 and 10 mg of Vortioxetine (Lu AA21004) in Acute Treatment of Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph2
  NCT00622245 · Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

  H. Lundbeck A/S · terminated · Depression in Patients With Bipolar Disorder · study director
• Ph2
  NCT00599911 · Dose-finding Study With Lu AA24530 in Major Depressive Disorder

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT00596817 · Efficacy of Vortioxetine (Lu AA21004) in the Prevention of Relapse of Major Depressive Episodes

  H. Lundbeck A/S · completed · Major Depressive Disorder · study director
• Ph3
  NCT00518713 · Clobazam in Patients With Lennox-Gastaut Syndrome

  Lundbeck LLC · completed · Epilepsy, Epilepsy, Generalized, Seizures · study director
• Ph2
  NCT00162981 · Clobazam in Subjects With Lennox-Gastaut Syndrome

  Lundbeck LLC · completed · Epilepsy, Epilepsy, Generalized, Seizures · study director
• Ph2
  NCT00125138 · Melperone (an Anti-Psychotic) in Patients With Psychosis Associated With Parkinson's Disease

  Lundbeck LLC · completed · Parkinson's Disease, Psychotic Disorders · study director

Grants

NIH projects from RePORTER, fetched 2026-11-12 11:58 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.